Prac-tic

RSS
Authorised

This medicine is authorised for use in the European Union

pyriprole
MedicineVeterinaryAuthorised
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

Prac-tic is a spot-on solution that contains pyriprole as active substance.

It is given to dogs with prefilled spot-on pipettes, i.e. small plastic containers that are already filled with the correct amount of Prac-tic needed to treat one dog (Pract-tic is available in four different sizes for different dog sizes). For large dogs, a combination of pipettes might be needed to achieve the correct dose. The content of the pipette is squeezed onto the skin after parting the fur in one up to three spots between the shoulder blades and down the backline of the dog.

Prac-tic is an 'ectoparasiticide', which means that it will kill parasites that live on the skin or in the fur of animals, such as fleas and ticks.

Prac-tic is used to treat and to prevent tick and flea infestations in dogs. Once applied, it remains active for at least four weeks.

Pyriprole interacts with a receptor involved in transmitting neural impulses (gamma-amino-butyric-acid (GABA) receptor). This interferes with the nervous system of fleas or ticks and leads to the death of these parasites. Adult fleas are killed before they lay eggs. Since Prac-tic completely eliminates egg production, it breaks the flea life cycle.

Data were provided on the pharmaceutical quality, the tolerance of the product in dogs and the safety in humans (people in contact with the product) and the environment.

The effectiveness of pyriprole against flea and tick infestations in dogs was investigated in laboratory studies and in field trials.

Two field studies were conducted in dogs at veterinary practices in several European countries and different geographic regions. Dogs from various breeds, age groups and weight that were infested with fleas or ticks were either treated with Prac-tic or with other products authorised in the European Union (EU) for this indication. The effectiveness was measured looking at the number of live ticks or number of fleas at various times up to three months after application.

The results of the field trials showed that Prac-tic is effective in the treatment and prevention of flea and tick infestations in dogs. The medicine killed fleas within 24 hours and ticks within 48 hours after treatment and its effectiveness lasted for at least four weeks.

The most common side effects in dogs are local reactions at the place where the product has been applied: change in the fur colour, hair loss and itchiness, as well as change in appearance of the fur (greasy appearance and clumpiness). If a dog licks the application area, the dog might salivate a lot for a short period.

Prac-tic should not be used in dogs less than eight weeks old or less than 2 kg bodyweight since it has not sufficiently been studied in these animals. As other products of this group, Prac-tic should not be used in sick animals or dogs that have just recovered from illness. This product is specifically developed for dogs and should not be used in any other animal species.

Prac-tic should not be allowed to enter surface water, as it may be harmful for aquatic organisms.

As a precautionary measure, direct contact with the treated dog should be avoided and children should not be allowed to play with a treated animal until the application site is dry. Recently treated animals should not be allowed to sleep in the same bed as their owners, especially children.

People with known hypersensitivity to the phenylpyrazole class compounds or any of the excipients should avoid contact with Prac-tic.

Skin contact with the pipette content should be avoided. Skin should be washed and eyes should be rinsed with water, if accidental exposure occurred. When administering Prac-tic, the user should not smoke, eat or drink.

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Prac-tic exceed the risks for the approved indications and recommended that Prac-tic be given a marketing authorisation. The benefit-risk balance may be found in the scientific discussion module of this EPAR.

The European Commission granted a marketing authorisation valid throughout the European Union for Prac-tic to on 18 December 2006. Information on the prescription status of this product may be found on the label / outer package.

български (BG) (105.24 KB - PDF)

View

español (ES) (101.95 KB - PDF)

View

čeština (CS) (125.02 KB - PDF)

View

dansk (DA) (101.2 KB - PDF)

View

Deutsch (DE) (102.33 KB - PDF)

View

eesti keel (ET) (99.62 KB - PDF)

View

ελληνικά (EL) (130.88 KB - PDF)

View

français (FR) (78.75 KB - PDF)

View

italiano (IT) (100.66 KB - PDF)

View

latviešu valoda (LV) (98.46 KB - PDF)

View

lietuvių kalba (LT) (124.16 KB - PDF)

View

magyar (HU) (120.76 KB - PDF)

View

Malti (MT) (103.94 KB - PDF)

View

Nederlands (NL) (101.18 KB - PDF)

View

polski (PL) (125.45 KB - PDF)

View

português (PT) (32.06 KB - PDF)

View

română (RO) (101.09 KB - PDF)

View

slovenčina (SK) (126.26 KB - PDF)

View

slovenščina (SL) (116.5 KB - PDF)

View

Suomi (FI) (108.42 KB - PDF)

View

svenska (SV) (101.29 KB - PDF)

View

Product information

български (BG) (294.81 KB - PDF)

View

español (ES) (177.38 KB - PDF)

View

čeština (CS) (260.23 KB - PDF)

View

dansk (DA) (153.1 KB - PDF)

View

Deutsch (DE) (165.7 KB - PDF)

View

eesti keel (ET) (168.11 KB - PDF)

View

ελληνικά (EL) (322.24 KB - PDF)

View

français (FR) (177.66 KB - PDF)

View

hrvatski (HR) (243.96 KB - PDF)

View

íslenska (IS) (170.59 KB - PDF)

View

italiano (IT) (229.48 KB - PDF)

View

latviešu valoda (LV) (263.09 KB - PDF)

View

lietuvių kalba (LT) (255.81 KB - PDF)

View

magyar (HU) (255.49 KB - PDF)

View

Malti (MT) (298.18 KB - PDF)

View

Nederlands (NL) (157.65 KB - PDF)

View

norsk (NO) (164.01 KB - PDF)

View

polski (PL) (281.23 KB - PDF)

View

português (PT) (164.85 KB - PDF)

View

română (RO) (280.32 KB - PDF)

View

slovenčina (SK) (281.97 KB - PDF)

View

slovenščina (SL) (244.06 KB - PDF)

View

Suomi (FI) (173.29 KB - PDF)

View

svenska (SV) (174.86 KB - PDF)

View
Latest procedure affecting product information: T/0025
27/08/2018

español (ES) (10.83 KB - PDF)

View

čeština (CS) (83.42 KB - PDF)

View

dansk (DA) (10.78 KB - PDF)

View

Deutsch (DE) (10.62 KB - PDF)

View

eesti keel (ET) (10.52 KB - PDF)

View

ελληνικά (EL) (76.81 KB - PDF)

View

français (FR) (10.68 KB - PDF)

View

italiano (IT) (10.17 KB - PDF)

View

latviešu valoda (LV) (80.94 KB - PDF)

View

lietuvių kalba (LT) (78.76 KB - PDF)

View

magyar (HU) (77.38 KB - PDF)

View

Nederlands (NL) (11.7 KB - PDF)

View

polski (PL) (81.09 KB - PDF)

View

português (PT) (10.88 KB - PDF)

View

slovenčina (SK) (82.06 KB - PDF)

View

slovenščina (SL) (40.22 KB - PDF)

View

Suomi (FI) (10.34 KB - PDF)

View

svenska (SV) (10.71 KB - PDF)

View

Product details

Name of medicine
Prac-tic
Active substance
pyriprole
International non-proprietary name (INN) or common name
pyriprole
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QP53AX26

Pharmacotherapeutic group

Ectoparasiticides for topical use, incl. insecticides

Therapeutic indication

Treatment and prevention of flea infestation (Ctenocephalides canis and C. felis) in dogs. Efficacy against new infestations with fleas persists for a minimum of 4 weeks.

Treatment and prevention of tick infestation (Ixodes ricinus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor reticulatus, Dermacentor variabilis, Amblyomma americanum) in dogs. Efficacy against ticks persists for 4 weeks.

Authorisation details

EMA product number
EMEA/V/C/000103
Marketing authorisation holder
Elanco GmbH

Heinz-Lohmann-Str 4
27472 Cuxhaven
Germany

Marketing authorisation issued
18/12/2006
Revision
10

Assessment history

This page was last updated on

Share this page